التفاصيل البيبلوغرافية
| العنوان: |
Effects of comicronised fenofibrate on lipid and insulin sensitivity in patients with polymetabolic syndrome X. |
| المؤلفون: |
Idzior-Walus, B.1, Sieradzki, J.1, Rostworowski, W.1, Zdzienicka, A.1, Kawalec, E.1, Wójcik, J.1, Żarnecki, A.1, Blane, G.2 |
| المصدر: |
European Journal of Clinical Investigation. Oct2000, Vol. 30 Issue 10, p871-878. 08p. |
| مصطلحات موضوعية: |
*FENOFIBRATE, *LIPID metabolism disorders, *THERAPEUTICS |
| مستخلص: |
Background This study investigated the effects of comicronised fenofibrate in patients with dyslipidemia and polymetabolic syndrome X. Design After a 6-week dietary run-in phase, 37 male patients eligible on lipid criteria entered a 12-week treatment phase consisting of diet plus one capsule daily containing 200 mg of comicronised fenofibrate (Lipanthyl®). Results A significant reduction in plasma concentrations of total cholesterol, LDL cholesterol and triglyceride was observed after 4, 8 and 12 weeks of treatment with fenofibrate. The improvement in the atherogenic index LDL/HDL cholesterol from a pretreatment 3.8 to 3.0 after treatment was highly statistically significant and may be judged as satisfactory. Significant changes were also observed in haemostatic factors (fibrinogen reduced by 19%, factor VII activity reduced by 18%). Fasting serum insulin levels and insulin response (area under the curve) after oral glucose load were significantly reduced by 26.8% and 18.7%, respectively, indicating an improvement of insulin sensitivity. Systolic and diastolic blood pressure were significantly reduced. Uric acid was significantly reduced by 21.6%. Conclusion These favourable effects of comicronised fenofibrate both on lipid and non lipid parameters, including insulin sensitivity, may confer to this product a particular interest in the treatment of patients with polymetabolic syndrome X. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
